REMEDY REMIX LIMITED

Executive Summary

REMEDY REMIX LIMITED is currently a dormant company with nominal net assets and no trading activity, reflecting a stable but inactive financial state. The company is compliant with statutory filing requirements, showing no signs of financial distress but also no active revenue generation. Moving forward, initiating business operations and strategic financial planning will be key to transitioning into a financially healthy and operationally active enterprise.

REMEDY REMIX LIMITED - Analysis Report

Company Number: 13801406

Analysis Date: 2025-07-29 20:33 UTC

Financial Health Assessment for REMEDY REMIX LIMITED

---

1. Financial Health Score: Grade C (Dormant Status - Minimal Financial Activity)

Explanation:
REMEDY REMIX LIMITED is currently classified as a dormant company with minimal financial transactions and negligible net assets (£100). The financial metrics reflect a company in a state of rest rather than active operation. While this status indicates no immediate financial distress, it also suggests an absence of revenue generation and operational activity, which limits traditional financial health analysis. The score reflects a neutral standing—no symptoms of financial distress, but also no signs of active business vitality.

---

2. Key Vital Signs

Metric	Value	Interpretation
Status	Active	Company is registered and operational but dormant (no trading).
Account Category	Dormant	No significant transactions during the financial year.
Net Assets	£100	Nominal equity, indicating minimal capital invested or retained.
Share Capital	£100	Paid-up share capital reflecting initial funding.
Current Liabilities	Not reported	Likely minimal or zero, consistent with dormant status.
Directors	1 (Marc Anthony Feldman)	Single director; no reported director disqualifications.
PSC (Significant Control)	Harkers Associates Limited (75-100% ownership)	Single controlling entity.
Filing Compliance	Up to date	No overdue accounts or confirmation statements.

Interpretation:
The vital signs suggest a company that has been set up but not yet activated into trading or operational mode. The balance sheet is essentially static, with nominal share capital and no recorded liabilities or assets beyond this. The company is compliant with filing deadlines and maintains a clear governance structure with a single director and a controlling shareholder.

---

3. Diagnosis

The "symptoms" of REMEDY REMIX LIMITED’s financial profile show a company in a dormant phase—a state akin to a patient in remission or hibernation rather than active treatment or growth. There is no indication of financial distress (no debts, no losses), but equally, there are no signs of business activity generating cash flow or profits. This means there is no "healthy cash flow" yet, but also no "symptoms of distress" such as liabilities or negative net assets.

The company appears stable but inactive, which is typical for newly incorporated entities awaiting operational commencement or held as a shelf company. The presence of a controlling shareholder with full voting rights suggests centralized control but does not provide insight into future plans.

---

4. Recommendations

• Activate Business Operations: To improve financial vitality, the company should consider initiating trading activities or investments to generate revenue and cash flow, moving beyond dormant status.

• Maintain Compliance: Continue timely filing of dormant accounts and confirmation statements to avoid penalties and maintain good standing.

• Monitor Cash and Funding Needs: Although currently minimal, plan for working capital requirements and ensure adequate funding through shareholder investments or financing once activities commence.

• Strategic Planning: Develop a clear business plan and financial projections to guide the transition from dormancy to active trading, allowing for early detection of potential financial "symptoms" such as cash flow shortages or increasing liabilities.

• Governance Review: Ensure director and shareholder roles are documented and prepared for the forthcoming operational phase, including risk management and compliance frameworks.

---